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The quantitative proteomics data here reported are part of a
research article entitled “Increased acute immune response during
the meningo-encephalitic stage of Trypanosoma brucei rhodesiense
sleeping sickness compared to Trypanosoma brucei gambiense”,
published by Tiberti et al., 2015. Transl. Proteomics 6, 1–9.
Sleeping sickness (human African trypanosomiasis – HAT) is a
deadly neglected tropical disease affecting mainly rural communities
in sub-Saharan Africa. This parasitic disease is caused by the
Trypanosoma brucei (T. b.) parasite, which is transmitted to the human
host through the bite of the tse-tse ﬂy. Two parasite sub-species, T. b.
rhodesiense and T. b. gambiense, are responsible for two clinically
different and geographically separated forms of sleeping sickness.
The objective of the present studywas to characterise and compare
the cerebrospinal ﬂuid (CSF) proteome of stage 2 (meningo-encepha-
litic stage) HAT patients suffering from T. b. gambiense or T. b.
rhodesiense disease using high-throughput quantitative proteomics
and the Tandem Mass Tag (TMTs) isobaric labelling. In order to
evaluate the CSF proteome in the context of HAT pathophysiology, the
protein dataset was then submitted to gene ontology and pathway
analysis. Two signiﬁcantly differentially expressed proteins (C-reactive
protein and orosomucoid 1) were further veriﬁed on a largerier Inc. This is an open access article under the CC BY license
Group, Department of Human Protein Sciences, University of Geneva,
.: þ41 22 3795486; fax: þ41 22 3795505.
(J.-C. Sanchez).
Department of Pathology, Sydney Medical School, The University of Sydney,
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spectrometry results. By showing a predominant involvement of the
acute immune response in rhodesiense HAT, the proteomics results
obtained in this work will contribute to further understand the
mechanisms of pathology occurring in HAT and to propose new
biomarkers of potential clinical utility. The mass spectrometry raw
data are available in the Pride Archive via ProteomeXchange through
the identiﬁer PXD001082.
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations table
Subject area Biomedicine
More speciﬁc
subject areaQuantitative proteomics, sleeping sickness, clinical biomarkersType of data Table of proteins signiﬁcantly differentially expressed (obtained with Isobar); list of all protein
identiﬁcations and quantiﬁcations (Excel ﬁle, Supplementary MS data)How data was
acquiredNSI-LTQ Orbitrap Velos (Thermo Electron)Data format MS/MS data analysed for identiﬁcation and quantiﬁcation
Experimental factors CSF samples were submitted to the modiﬁed single centrifugation sample preparation for sleeping
sickness diagnostic purposes, as described by Miezan et al. [1]. For each patients, 60 mL of CSF was used
for the proteomics sample preparation.Experimental
featuresCSF samples were analysed by quantitative proteomics. Proteins were digested with trypsin and labelled
with the TMT 6-plex reagents. The pooled labelled sample was subjected to off-gel electrophoresis (OGE)
fractionation (12 fractions) prior to LC–MS/MS analysis of each individual fraction.Data source location Samples were collected in the Democratic Republic of the Congo and in Uganda. All the analyses
(quantitative proteomics, data analysis) have been performed in Geneva (Switzerland).Data accessibility Data are publicly available via ProteomeXchange and can be accessed through the identiﬁer PXD001082
(http://www.ebi.ac.uk/pride/archive/projects/PXD001082)1. Value of the data The TMT quantitative approach is a powerful tool to characterise and compare CSF proteome.
 The combination of proteomic and bioinformatics is useful to understand HAT pathophysiology.
 Quantitative proteomic showed that T. b. rhodesiense strongly evokes innate immunity activation.2. Experimental design, materials and methods
2.1. Experimental design
In the present work we investigated the cerebrospinal ﬂuid (CSF) from T. b. gambiense (n¼3) and T.
b. rhodesiense (n¼3) HAT patients using TMT quantitative proteomics. The quantitative analyses,
performed on the identiﬁed proteins, highlighted proteins differentially expressed between the two
forms of HAT. The proteomics data here presented, are part of a larger investigation on the biological
mechanisms and pathways speciﬁcally associated to the rhodesiense form of HAT when compared to
the gambiense one, published in 2015 [2]. The complete experimental design involving the proteomics
investigations here reported is represented in Fig. 1.
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HAT patients investigated by quantitative proteomics were enrolled in the Democratic Republic of
the Congo (D.R.C.) and in Uganda, as part of prospective studies already published elsewhere [3,4]. The
relevant Institutional and National Ethics Committees of the D.R.C., Uganda and Belgium approved the
respective studies. All participants signed a written informed consent, accepted to be enrolled in the
studies and had the possibility to withdraw at any moment.
Patients were diagnosed and staged for sleeping sickness according to the guidelines of the
national sleeping sickness control programs of the country of sample collection. For the present study,
patients were classiﬁed as stage 2 (i.e., presence of parasites in CSF and/or CSF WBC count 45 cells/
ml) following WHO guidelines [5].Fig. 1. Graphical representation of the complete experimental design of the study involving the TMT 6-plex experiment and
dataset described.
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for parasite detection [1]. Our proteomics analyses were performed on the supernatant of this
centrifugation. All CSF samples here investigated were collected before treatment administration.
2.3. Proteomics
2.3.1. Samples
CSF samples (n¼6) obtained from 6 HAT patients were investigated. Among them, 3 patients
suffered from S2 T. b. gambiense HAT and originated from the D.R.C. [3] and 3 patients suffered from S2
T. b. rhodesiense and originated from endemic regions in Uganda – Serere district (FINDTRYP study)
[4]. The demographic description of the patients is reported in Table 1.
2.3.2. Sample preparation and peptide labelling
For each sample, 60 mL of CSF was used. An internal control was spiked in each sample (0.5 mg of
bovine beta-lactoglobulin, SigmaAldrich). Proteins were then reduced with 50 mM tris(2-carbox-
yethyl)phosphine (TCEP) and alkylated with 400 mM iodoacetamide, prior to digestion into peptides
with trypsin 0.2 mg/mL (Promega).
Digested samples were labelled with the TMTs 6-plex tagging reagents (Thermo Fisher Scientiﬁc)
following manufacturer's instructions. T. b. gambiense samples were labelled with the tags TMT-126,
TMT-127 and TMT-128, while T. b. rhodesiense samples were labelled with the tags TMT-129, TMT-130
and TMT-131 (Table 1). After tagging, the 6 samples were pooled, dried under vacuum and desalted
with C18 Macro Spin Columns (Harvard Apparatus).
The pooled sample was then fractionated by off-gel electrophoresis (OGE – Agilent) into 12 fractions
using a 13 cm, pH 3–10 linear IPG strip (GE Healthcare). Each OGE fraction was desalted with C18 Micro
Spin Columns (Harvard Apparatus), dried under vacuum and analysed by tandemmass spectrometry [6,7].
2.3.3. Mass spectrometry analyses
MS analyses were performed on a nanoelectrospray ionisation (NSI) LTQ Orbitrap (OT) velos from
Thermo Electron equipped with a NanoAcquity system from Waters. Peptides were trapped on a
home-made 5 mm 200 Å Magic C18 AQ (Michrom) 0.120 mm2 pre-column and separated on a
home-made 5 mm 100 Å Magic C18 AQ (Michrom) 0.75150 mm2 column with a gravity-pulled
emitter. A gradient of 65 min was applied for the analytical separation using H2O/formic acid (FA)
99.9%/0.1% as solvent A and CH3CN/FA 99.9%/0.1% as solvent B. The gradient was run at a ﬂow rate of
220 nL/min as follows: 0–1 min 5% B, to 35% B at 55 min and then to 80% B at 65 min.
For MS survey scans, the OT resolution was set to 60,000 and the ion population was set to 5105
with an m/z window from 400 to 2000. A maximum of 3 precursors were selected for both collision-
induced dissociation (CID) in the LTQ and higher energy collision dissociation (HCD) with analysis in
the OT. For MS/MS in the LTQ, the ion population was set to 7000 (isolation width of 2 m/z) while for
MS/MS detection in the OT, it was set to 2105 (isolation width of 2.5 m/z), with resolution of 7500,
ﬁrst mass at m/z¼100 and maximum injection time of 750 ms. The normalised collision energies
were set to 35% for CID and 60% for HCD [7].Table 1
Demographic description of patients investigated in the TMT 6-plex experiment.
T. b. gambiense - D.R.C. T. b. rhodesiense - UGANDA
PT 1 PT 2 PT 3 PT 4 PT 5 PT 6
Sex F F F F F F
Age 21 29 51 22 30 53
TþCSF Yes Yes Yes Yes Yes Yes
WBC/mL 135 217 97 119 231 70
TMT TAG 126 127 128 129 130 131
Tþ CSF: presence of parasites in the CSF, WBC/mL: number of leucocytes/mL of CSF.
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Protein identiﬁcation was obtained with the EasyProt platform v2.3 [8]. After peak list generation
using ReadW software, CID and HCD spectra were merged to obtain the simultaneous identiﬁcation
and quantiﬁcation [7].
Proteins were identiﬁed by searching peptide spectral matches against the Swiss-Prot/UniProt
database (Version 13-June-2012, 5360489 entries) choosing the Homo sapiens taxonomy. For EasyProt
protein search, carbamidomethylation of cysteines, TMT six-plex amino-termini and TMT six-plex
lysines were set as ﬁxed modiﬁcations, while oxidised methionines as variable. Trypsin was selected
as the digestion enzyme with only 1 missed-cleavage allowed, only peptides with a minimum of
6 residues were selected for identiﬁcation and the precursor ion tolerance was set to 10 ppm.
The efﬁcient technical performance of the experiment was evaluated through the peptide labelling
rate (over 93%) and the technical variability through the peptide relative intensity distribution of the
bovine beta-lactoglobulin among the 6 channels (CVo17%).
Only proteins identiﬁed with at least 2 unique peptides and with an FDRr1% (computed at the
PSM level) were considered for further quantitative analyses using Isobar quantiﬁcation tool (version
1.76) [9], embedded in EasyProt. Only peptides speciﬁc for a unique entry in the job were taken into
account for protein quantiﬁcation. The isotopic purity correction (according to the algorithm given by
the manufacturer) of each channel and the Isobar default normalisation [9] were applied. Finally, the
protein ratio T. b. rhodesiense/T. b. gambiense was computed according to the tagging design, i.e.
TMT129þ130þ131/TMT126þ127þ128 and the ratio and sample p-Values were calculated by the
software [9]. Proteins having both ratio p-Value (estimator of ratio accuracy relative to the quality of
the spectra) and sample p-Value (estimator of the biological variability) signiﬁcant were considered as
differentially expressed. The list of proteins signiﬁcantly differentially expressed is reported in Table 2.
The mass spectrometry raw data were deposited into the ProteomeXchange Consortium
(http://proteomecentral.proteomexchange.org) [10] via the PRIDE partner repository [11] with the
dataset identiﬁer PXD001082.
The list of identiﬁed (n¼239) and quantiﬁed (n¼222) proteins, with the respective protein ratio
and statistics is reported in Supplementary MS data (Tables S1 and S2).2.3.5. Gene ontology and pathway analyses
The experimental protein dataset was then evaluated in the context of HAT pathophysiology. To
point out speciﬁc mechanisms signiﬁcantly associated to one of the two forms of sleeping sickness,Table 2
List of proteins signiﬁcantly differentially expressed between rhodesiense and gambiense S2 CSF. Only proteins identiﬁed with at
least 2 unique peptides and FDRo1% were considered for quantiﬁcation.
AC Protein Gene Peptide
count
Spectral
count
Ration p Value
ratio
p Value
sample
1 P06311 Ig kappa chain V–III region IARC/
BL41
Na 2 2 0.69 0.007 0.002
2 O00584 Ribonuclease T2 RNASET2 3 3 0.69 0.006 0.019
3 Q9NPR2 Semaphorin-4B SEMA4B 2 2 0.72 0.048 0.017
4 P04114 Apolipoprotein B-100 APOB 4 5 1.36 0.041 0.045
5 P19652 Alpha-1-acid glycoprotein 2 ORM2 5 10 1.49 0.005 0.017
6 Q03591 Complement factor H-related
protein 1
CFHR1 1 1 1.52 0.023 0.036
7 P02748 Complement component C9 C9 8 10 1.78 0.006 0.003
8 Q14624 Inter-alpha-trypsin inhibitor heavy
chain H4
ITIH4 10 18 1.80 0.005 0.026
9 P18428 Lipopolysaccharide-binding protein LBP 2 2 2.31 0.046 0.000
10 P02763 Alpha-1-acid glycoprotein 1 ORM1 6 28 2.69 0.001 0.000
11 P02741 C-reactive protein CRP 3 5 9.30 0.001 0.000
Peptide count and spectral count correspond to the number of peptides and of spectra used for the quantiﬁcation, respectively.
n T. b. rhodesiense/T. b. gambiense [129þ130þ131/126þ127þ128].
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Ingenuity) and gene ontology (GO – BioCompendium) analyses, respectively.Conﬂict of interest
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